AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 92 min read$ARQT

Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and steroid use at dermatology conferences. Phase 2 data showed 34.4% of infants with atopic dermatitis achieved clear or almost clear skin after 4 weeks. Phase 3 data showed 66.4% of patients with scalp psoriasis achieved clear or almost clear skin at Week 8. The company also presented research on seborrheic dermatitis and corticosteroid hesitancy. ARQT stock was up 1.32% on Thursday and is up 1.84% in premarket trading.

Original reporting
rttnews.com
Published Oct 9, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Arcutis Shares New Dermatology Data On ZORYVE And Steroid Use; Stock Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$ARQTBullishMed
01

Why it matters

The disclosed efficacy numbers provide the first public evidence of ZORYVE's potential across multiple skin conditions, a catalyst for valuation.

02

Market read

Positive trial data may drive short‑term buying interest and set the stage for future regulatory filings.

03

What to watch

Regulatory timelines and competitive pipeline from larger dermatology players may temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Arcutis presented data at the European Academy of Dermatology and Venereology Congress and the Fall Clinical Dermatology Conference.

Company-level read

Ticker impact

$ARQTBullishHigh confidence
Context

Arcutis Biotherapeutics released new Phase 2 and Phase 3 trial data for its ZORYVE (roflumilast) dermatology treatments, showing clear or almost clear skin rates well above vehicle controls.

Expected impact

upside pressure as the market prices in the encouraging efficacy data

Evidence & confidence

Clear‑skin response rates of 34.4% in infants and 66.4% in Phase 3 patients exceed expectations and suggest a viable product pipeline.

Market effects

Sector

Dermatology biotech sector may see heightened interest in roflumilast‑based therapies.

Regional

US biotech investors likely to react; limited immediate effect on broader markets.

Global

Data could influence global investors tracking emerging dermatology treatments.

Counterpoint

What could challenge this read

If later-stage trials fail to confirm these early results, the stock could face sharp downside.

Key entities

  • company
    Arcutis Biotherapeutics

    US‑listed biotech developing dermatology treatments.

  • product
    ZORYVE (roflumilast)

    Investigational topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 9
$ARQTHighAI 8/10

Arcutis Presents ZORYVE Data At Dermatology Meetings; Stock Up

Arcutis Biotherapeutics (ARQT) shared new data on ZORYVE (roflumilast) and long-term topical corticosteroid use at dermatology meetings. The data showed improvements in atopic dermatitis and psoriasis symptoms. ARQT's stock closed at $24.49, up 1.32%, and was up 1.84% in premarket trading.

rttnews.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis presents data on ZORYVE cream for infant eczema

Arcutis Biotherapeutics presented clinical trial data for ZORYVE cream in infants with eczema, showing 34.4% achieved clear or almost clear skin. The treatment had no serious adverse events. The company also shared data on ZORYVE foam for psoriasis, with 66.4% of patients achieving clear or almost clear scalp skin. Arcutis is seeking FDA approval for ZORYVE cream in infants, with a decision expected in 2027.

investing.com2 min
OCT 9
$ARQTMedAI 8/10

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis Biotherapeutics (ARQT) presented data on ZORYVE (roflumilast) at EADV and Fall Clinical Dermatology Conference. The company shared results from the INTEGUMENT-INFANT trial for infants with atopic dermatitis, ARRECTOR and DERMIS-1/2 trials for psoriasis, and collaborative research on seborrheic dermatitis. Additionally, Arcutis presented real-world data on topical corticosteroid use in chronic inflammatory skin conditions.

globenewswire.com2 min
AUG 5
$ARQTHigh

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min